ResearchingRefreshing VKTX from the latest filings.
1 of 8 sections ready
As of Sep 7, 2026, 11:11 PM
Price Chart
Overview
Viking Therapeutics is a clinical-stage biotechnology company developing medicines for obesity and other metabolic and hormone-related diseases, and it has no marketed product as of June 30, 2026. Its most important program is VK2735, an obesity drug designed to activate two natural gut-hormone pathways and being tested in both injectable and oral forms. The injectable version was in Phase 3 studies that were fully enrolled as of June 30, 2026, while the company expected to begin a Phase 3 oral study in the fourth quarter of 2026.
The opportunity is a potentially valuable obesity franchise with both injectable and oral versions of VK2735, supported by $502 million of cash and cash equivalents as of June 30, 2026, and 116,652,937 shares outstanding as of July 15, 2026. The key risk is that Viking remains dependent on clinical and regulatory success, has no marketed product or established product-sales revenue as of June 30, 2026, and may need additional equity financing; it entered into a new at-the-market equity offering agreement on July 29, 2026.